{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:42Z","timestamp":1782337242547,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":1307,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Particle Therapy"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.14338\/ijpt-20-00004.1","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T15:36:32Z","timestamp":1591198592000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?"],"prefix":"10.1016","volume":"7","author":[{"given":"Omran","family":"Saifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef H.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14338\/IJPT-20-00004.1_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.14338\/IJPT-20-00004.1_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","article-title":"New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy","volume":"15","author":"Chihara","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.14338\/IJPT-20-00004.1_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.14338\/IJPT-20-00004.1_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of Radiation Therapy in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib7","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"10.14338\/IJPT-20-00004.1_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.14338\/IJPT-20-00004.1_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib12","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","author":"Biswas","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib14","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib15","article-title":"CAR-T cell therapy for lymphoma: how does radiation therapy fit in","author":"Dreyfuss","year":"2019","journal-title":"Pract Radiat Oncol."},{"key":"10.14338\/IJPT-20-00004.1_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-019-1360-7","article-title":"Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease","volume":"14","author":"Lautenschlaeger","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.14338\/IJPT-20-00004.1_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.14338\/IJPT-20-00004.1_bib19","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"10.14338\/IJPT-20-00004.1_bib20","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.14338\/IJPT-20-00004.1_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J Immunother"},{"key":"10.14338\/IJPT-20-00004.1_bib22","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.14338\/IJPT-20-00004.1_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"10.14338\/IJPT-20-00004.1_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.14338\/IJPT-20-00004.1_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","author":"Turtle","year":"2016","journal-title":"Sci Transl Med."},{"key":"10.14338\/IJPT-20-00004.1_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"10.14338\/IJPT-20-00004.1_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.14338\/IJPT-20-00004.1_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.14338\/IJPT-20-00004.1_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.14338\/IJPT-20-00004.1_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"10.14338\/IJPT-20-00004.1_bib33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","author":"Tseng","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bmt.2008.408","article-title":"The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"43","author":"Hoppe","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.14338\/IJPT-20-00004.1_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib38","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3109\/10428194.2015.1014364","article-title":"Proton therapy in the management of non-Hodgkin lymphoma","volume":"56","author":"Sachsman","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.14338\/IJPT-20-00004.1_bib39","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/j.ijrobp.2018.07.1061","article-title":"Bi-institutional report on consolidative proton therapy after initial chemotherapy for mediastinal diffuse large B-cell and primary mediastinal large B-cell lymphomas","volume":"102","author":"Plastaras","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2005.09.030","article-title":"Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma","volume":"64","author":"Martens","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib41","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"10.14338\/IJPT-20-00004.1_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"},{"key":"10.14338\/IJPT-20-00004.1_bib43","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.14338\/IJPT-20-00004.1_bib44","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ijrobp.2019.06.514","article-title":"Induction radiation prior to commercial chimeric antigen receptor T-cell therapy for relapsed\/refractory non-Hodgkin lymphoma","volume":"105","author":"LaRiviere","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib45","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.ijrobp.2018.06.306","article-title":"Tandem induction radiation and chimeric antigen receptor T cell therapy in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Arscott","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib46","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hon.68_2630","article-title":"MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy","volume":"37","author":"Imber","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clml.2014.02.012","article-title":"Clinical efficacy and safety in relapsed\/refractory diffuse large B-cell lymphoma: a systematic literature review","volume":"14","author":"Colosia","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.14338\/IJPT-20-00004.1_bib49","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jcyt.2017.02.190","article-title":"Joseph Melenhorst J, June C, Schuster S, Levine BL. Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in non-Hodgkin lymphoma (NHL)","volume":"19","author":"Davis","year":"2017","journal-title":"Cytotherapy"},{"key":"10.14338\/IJPT-20-00004.1_bib50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib51","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.14338\/IJPT-20-00004.1_bib52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.14338\/IJPT-20-00004.1_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.adro.2018.09.004","article-title":"A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer","volume":"4","author":"Routman","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.14338\/IJPT-20-00004.1_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14338\/IJPT-17-00033.1","article-title":"Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation","volume":"4","author":"Fang","year":"2018","journal-title":"Int J Particle Ther"},{"key":"10.14338\/IJPT-20-00004.1_bib55","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14737167.2019.1680288","article-title":"Cost burden of diffuse large B-cell lymphoma","volume":"19","author":"Harkins","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.14338\/IJPT-20-00004.1_bib56","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/0284186X.2016.1197422","article-title":"Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry","volume":"55","author":"Hoppe","year":"2016","journal-title":"Acta Oncol"}],"container-title":["International Journal of Particle Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2331518023001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2331518023001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/theijpt\/article-pdf\/7\/1\/13\/2576828\/i2331-5180-7-1-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/theijpt\/article-pdf\/7\/1\/13\/2576828\/i2331-5180-7-1-13.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:32:54Z","timestamp":1762421574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2331518023001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2331518023001531"],"URL":"https:\/\/doi.org\/10.14338\/ijpt-20-00004.1","relation":{},"ISSN":["2331-5180"],"issn-type":[{"value":"2331-5180","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Particle Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14338\/IJPT-20-00004.1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 \u00a9 2020 THE AUTHORS. Published by Elsevier BV on behalf of the Particle Therapy Co-operative Group. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}